Evidence map›Paper›PMID 40849415›Full record

ArticleNature communications2025

SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults.

Carolyn A Cohen, Ludivine Grzelak, Susan S Chiu, David Sc Hui, Mike Yw Kwan, Owen Ty Tsang, Wai Hung Chan, Yat Sun Yau, Kelly Wk Lee, Masashi Mori and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Carolyn A Cohen *HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Ludivine Grzelak *Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.ORCID http://orcid.org/0000-0002-1298-7565
Susan S ChiuDepartment of Paediatric and Adolescent Medicine, The University of Hong Kong and Queen Mary Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China.
David Sc HuiDepartment of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China.ORCID http://orcid.org/0000-0003-4382-2445
Mike Yw KwanDepartment of Paediatric and Adolescent Medicine, Hong Kong Hospital Authority Infectious Disease Centre, Princess Margaret Hospital, Hong Kong SAR, China.
Owen Ty TsangInfectious Diseases Centre, Princess Margaret Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China.
Wai Hung ChanDepartment of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China.ORCID http://orcid.org/0000-0002-9256-4799
Yat Sun YauDepartment of Paediatrics, Queen Elizabeth Hospital, Hospital Authority of Hong Kong, Hong Kong SAR, China.ORCID http://orcid.org/0000-0002-5471-9139
Kelly Wk LeeHKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Masashi MoriResearch Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Nonoichi, Ishikawa, Japan.
Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0418-9707
Samuel Ms ChengDivision of Public Health Laboratory Sciences, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID http://orcid.org/0000-0001-7293-2331
Leo Lm PoonHKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID http://orcid.org/0000-0002-9101-7953
Malik PeirisHKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.ORCID http://orcid.org/0000-0001-8217-5995
Sophie A ValkenburgHKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. sophie.v@unimelb.edu.au.ORCID http://orcid.org/0000-0002-0768-9926

Funding

Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (HMRF) COVID190126 and 190115NIAID NIH HHS HHSN272201400006C
6 · The paper itself

Abstract

As intrinsic differences in humoral immune response to SARS-CoV-2 between children and adults remain unclear, we improved characterisation by defining the kinetics, specificity and function of antibodies to SARS-CoV-2 in children (n = 146, aged 9.4 ± 4.8 years with n = 257 samples) compared to adults (n = 85, aged 39.5 ± 15.2 years with n = 122 samples). We used plasma samples from an infection and vaccination-naive cohort study with RT-PCR confirmed ancestral B.1* SARS-CoV-2 virus infection with asymptomatic or mild disease, collected in Hong Kong between March to December 2020, from acute (0-14 days post infection) to convalescent (15-206 days) timepoints. Children had significantly lower primary antibody responses against SARS-CoV-2 proteins overall, leading to a less isotype switched response. While children had lower OC43 Spike and SARS-CoV-2 S2 IgG and avidity than adults, they exhibited higher avidities for SARS-CoV-2 whole Spike and Nucleocapsid, and higher levels of Spike FcγR-binding antibodies. Adults' SARS-CoV-2 antibody responses could be derived from high avidity pre-existing cross-reactive common cold coronavirus B cell responses, whilst children appear to generate a de novo SARS-CoV-2- specific Spike and Nucleocapsid IgG with robust Fc receptor (FcR) binding ability and high avidity at a higher proportion than adults, thus their responses are more targeted and functional for SARS-CoV-2.

Indexed as

Antibodies, ViralAntibody AffinityCOVID-19SARS-CoV-2AdolescentAdultAntibodies, NeutralizingChildChild, PreschoolCohort StudiesFemaleHong KongHumansImmunoglobulin GMaleMiddle AgedAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID40849415
PMCPMC12375124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.